BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33941880)

  • 1. Loss-of-function and missense variants in NSD2 cause decreased methylation activity and are associated with a distinct developmental phenotype.
    Zanoni P; Steindl K; Sengupta D; Joset P; Bahr A; Sticht H; Lang-Muritano M; van Ravenswaaij-Arts CMA; Shinawi M; Andrews M; Attie-Bitach T; Maystadt I; Belnap N; Benoit V; Delplancq G; de Vries BBA; Grotto S; Lacombe D; Larson A; Mourmans J; Õunap K; Petrilli G; Pfundt R; Ramsey K; Blok LS; Tsatsaris V; Vitobello A; Faivre L; Wheeler PG; Wevers MR; Wojcik M; Zweier M; Gozani O; Rauch A
    Genet Med; 2021 Aug; 23(8):1474-1483. PubMed ID: 33941880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: A
    Yang Q; Gong D; Yi S; Luo J; Zhang Q
    Front Pediatr; 2023; 11():1064783. PubMed ID: 37351323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo truncating variant in NSD2gene leading to atypical Wolf-Hirschhorn syndrome phenotype.
    Jiang Y; Sun H; Lin Q; Wang Z; Wang G; Wang J; Jiang F; Yao R
    BMC Med Genet; 2019 Aug; 20(1):134. PubMed ID: 31382906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The constitutional gain-of-function variant p.Glu1099Lys in NSD2 is associated with a novel syndrome.
    Popp B; Brugger M; Poschmann S; Bartolomaeus T; Radtke M; Hentschel J; Di Donato N; Rump A; Gburek-Augustat J; Graf E; Wagner M; Sorge I; Lemke JR; Meitinger T; Abou Jamra R; Strehlow V; Brunet T
    Clin Genet; 2023 Feb; 103(2):226-230. PubMed ID: 36189577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The first familial NSD2 cases with a novel variant in a Chinese father and daughter with atypical WHS facial features and a 7.5-year follow-up of growth hormone therapy.
    Hu X; Wu D; Li Y; Wei L; Li X; Qin M; Li H; Li M; Chen S; Gong C; Shen Y
    BMC Med Genomics; 2020 Dec; 13(1):181. PubMed ID: 33276791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correspondence on "Loss-of-function and missense variants in NSD2 cause decreased methylation activity and are associated with a distinct developmental phenotype" by Zanoni et al.
    Cueto-González AM; Fernández-Álvarez P; Palafoll IV; Lasa-Aranzasti A; Vendrell Bayona T; Tizzano EF
    Genet Med; 2022 Mar; 24(3):754-756. PubMed ID: 34906509
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical details of individuals with Rauch-Steindl syndrome due to NSD2 truncating variants.
    Nishi E; Yanagi K; Kaname T; Okamoto N
    Mol Genet Genomic Med; 2024 Feb; 12(2):e2396. PubMed ID: 38353053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From Wolf-Hirschhorn syndrome to NSD2 haploinsufficiency: a shifting paradigm through the description of a new case and a review of the literature.
    Wiel LC; Bruno I; Barbi E; Sirchia F
    Ital J Pediatr; 2022 May; 48(1):72. PubMed ID: 35550183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo loss-of-function variants in
    Barrie ES; Alfaro MP; Pfau RB; Goff MJ; McBride KL; Manickam K; Zmuda EJ
    Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 31171569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental delay and failure to thrive associated with a loss-of-function variant in WHSC1 (NSD2).
    Boczek NJ; Lahner CA; Nguyen TM; Ferber MJ; Hasadsri L; Thorland EC; Niu Z; Gavrilova RH
    Am J Med Genet A; 2018 Dec; 176(12):2798-2802. PubMed ID: 30345613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically unresolved case of Rauch-Steindl syndrome diagnosed by its wolf-hirschhorn associated DNA methylation episignature.
    McConkey H; White-Brown A; Kerkhof J; Dyment D; Sadikovic B
    Front Cell Dev Biol; 2022; 10():1022683. PubMed ID: 36589751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo truncating variants in WHSC1 recapitulate the Wolf-Hirschhorn (4p16.3 microdeletion) syndrome phenotype.
    Derar N; Al-Hassnan ZN; Al-Owain M; Monies D; Abouelhoda M; Meyer BF; Moghrabi N; Alkuraya FS
    Genet Med; 2019 Jan; 21(1):185-188. PubMed ID: 29892088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome.
    Nimura K; Ura K; Shiratori H; Ikawa M; Okabe M; Schwartz RJ; Kaneda Y
    Nature; 2009 Jul; 460(7252):287-91. PubMed ID: 19483677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NSD2 promotes ventricular remodelling mediated by the regulation of H3K36me2.
    Zhou XL; Zhu RR; Wu X; Xu H; Li YY; Xu QR; Liu S; Huang H; Xu X; Wan L; Wu QC; Liu JC
    J Cell Mol Med; 2019 Jan; 23(1):568-575. PubMed ID: 30334333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 109 kb deletion of chromosome 4p16.3 in a patient with mild phenotype of Wolf-Hirschhorn syndrome.
    Okamoto N; Ohmachi K; Shimada S; Shimojima K; Yamamoto T
    Am J Med Genet A; 2013 Jun; 161A(6):1465-9. PubMed ID: 23637096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo nonsense mutation in WHSC1 (NSD2) in patient with intellectual disability and dysmorphic features.
    Lozier ER; Konovalov FA; Kanivets IV; Pyankov DV; Koshkin PA; Baleva LS; Sipyagina AE; Yakusheva EN; Kuchina AE; Korostelev SA
    J Hum Genet; 2018 Jul; 63(8):919-922. PubMed ID: 29760529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36.
    Poulin MB; Schneck JL; Matico RE; McDevitt PJ; Huddleston MJ; Hou W; Johnson NW; Thrall SH; Meek TD; Schramm VL
    Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1197-201. PubMed ID: 26787850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletions involving genes WHSC1 and LETM1 may be necessary, but are not sufficient to cause Wolf-Hirschhorn Syndrome.
    Andersen EF; Carey JC; Earl DL; Corzo D; Suttie M; Hammond P; South ST
    Eur J Hum Genet; 2014 Apr; 22(4):464-70. PubMed ID: 23963300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wolf-Hirschhorn Syndrome Candidate 1 (whsc1) Functions as a Tumor Suppressor by Governing Cell Differentiation.
    Yu C; Yao X; Zhao L; Wang P; Zhang Q; Zhao C; Yao S; Wei Y
    Neoplasia; 2017 Aug; 19(8):606-616. PubMed ID: 28654864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.
    Swaroop A; Oyer JA; Will CM; Huang X; Yu W; Troche C; Bulic M; Durham BH; Wen QJ; Crispino JD; MacKerell AD; Bennett RL; Kelleher NL; Licht JD
    Oncogene; 2019 Jan; 38(5):671-686. PubMed ID: 30171259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.